Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cidofovir with radiotherapy in HPV-positive oropharyngeal cancer
NL-OMON33865Not yet recruiting
- Sponsor
- initiator = sponsor
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cidofovir in oropharyngeal cancer, sponsored by initiator = sponsor. Primary endpoint: Maximum tolerated dose of cidofovir in combination with radiotherapy. Planned start Mar 2009; status: not yet recruiting.
02
Drugs
cidofovir
03
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on NL-OMON33865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33865.